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Kynurenic acid (KYNA), a product of the kynurenine pathway (KP) of tryptophan 
degradation, antagonizes both the α7 nicotinic acetylcholine receptor (α7nAChR) and the 
glycine co-agonist (glycineB) site of the NMDA receptor (NMDAR) at nanomolar to low 
micromolar concentrations. As these two receptors play central roles in brain physiology 
and pathology, and as the concentration of KYNA in the mammalian brain may be 
sufficient to affect both receptors in vivo, fluctuations in endogenous KYNA levels might 
regulate neurotransmission and also play a role in pathological events involving 
α7nAChRs and NMDARs (Schwarcz et al. 2012). So far, no efforts have been made to 
investigate in vivo the possibility that endogenous KYNA might influence the levels of 
glutamate and γ-aminobutyric acid (GABA) in the striatum and in the prefrontal cortex 
(PFC), effects that may have significant physiological consequences and may also have 
implications for pathological events. In fact, a dysfunction of circuits involving PFC GABA 
and glutamate neurons plays an important role in the cognitive deficits seen in patients 
with schizophrenia (SZ) (Volk and Lewis, 2010). Interestingly, another well-known 
pathophysiology in SZ, which may exacerbate neurotransmitter dysregulations in the 
disease, is the disruption of the KP of tryptophan degradation (Schwarcz et al., 2001). 
Furthermore, the great majority of striatal neurons and intrinsic synapses are GABAergic, 
making GABA a key player in the widespread lateral inhibitory network in the region. 
Finally, GABAergic neurons in the human neostriatum are exquisitely vulnerable in 
Huntington’s disease and may be involved in the pathophysiology of SZ, two brain 
diseases with purported links to striatal KYNA dysfunction (Beal et al. 1990, Rassoulpour 
et al. 2006).  
In view of above, using a microdialysis approach in awake, freely moving rats, the effects 
of exogenous or endogenous KYNA levels manipulations on extracellular glutamate and 
GABA levels in the striatum and in the PFC have been evaluated.  
Applied for 2 hrs by reverse dialysis, KYNA concentration-dependently reduced 
extracellular glutamate and GABA levels in both brain regions, with 300 nM KYNA causing 
the maximal decreases. These effects were not duplicated by reverse dialysis of the 
selective glycineB receptor antagonist 7-Cl-KYNA (100 nM) or the AMPA/kainate receptor 
antagonist CNQX (100 µM). On the contrary, the effects of KYNA were prevented by the 
co-application of galantamine (5 μM), a positive allosteric modulator that binds at a site of 
the α7nAChR that is very similar to that targeted by KYNA. Galantamine did not affect 
glutamate and GABA levels on its own in the PFC, while it moderately, but significantly, 
increased local striatal glutamate and GABA levels.  
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In a separate set of experiments, endogenous KYNA formation was inhibited by reverse 
dialysis of (S)-4-(ethylsulfonyl)benzoylalanine (ESBA; 1 and 5 mM), a specific inhibitor of 
kynurenine aminotransferase II, KYNA’s major biosynthetic enzyme in the brain (Pellicciari 
et al., 2006). ESBA reversibly increased glutamate and GABA levels in the rat striatum and 
PFC, reaching a peak of ~160% of baseline levels. Co-infusion of 100 nM KYNA abolished 
the effect of ESBA on striatal and PFC glutamate and GABA, confirming the specificity of 
the ESBA effect.  
Taken together, these results indicate that fluctuations in the endogenous formation of 
KYNA bi-directionally influence extracellular glutamate and GABA levels in the rat striatum 
and PFC. This tonic regulation, which appears to be mediated by α7nAChRs, suggests a 
role of astrocyte-derived KYNA in the control of aminoacidergic neurotransmission in both 
brain areas. As cortical KYNA levels are elevated in SZ, and in light of evidence indicating 
reduced GABA neurotransmission in SZ, our findings suggest that drugs capable of 
attenuating the production of KYNA may be of benefit in the treatment of cognitive deficits 
in SZ. In addition, in light of the central role of glutamate and GABA in striatal physiology, 
this study indicates that KYNA should be considered as an endogenous modulator of 
major biological functions involving the striatum, ranging from motor behavior to reward 
signaling and cognitive processes. 
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